Aravive, Inc. (ARAV) News

Aravive, Inc. (ARAV): $1.38

0.04 (+2.99%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ARAV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 380

in industry

Filter ARAV News Items

ARAV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ARAV News Highlights

  • ARAV's 30 day story count now stands at 6.
  • Over the past 14 days, the trend for ARAV's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about ARAV are NOV, PROC and BEAT.

Latest ARAV News From Around the Web

Below are the latest news stories about ARAVIVE INC that investors may wish to consider to help them evaluate ARAV as an investment opportunity.

Aravive To Participate in Piper’s 34th Annual Healthcare Conference

HOUSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will be presenting a corporate overview and participating in 1x1 meetings at the Piper 34th Annual Healthcare Conference being held on November 29 – December 1, 2022 in New York, NY. Piper 34th Annual Healthcare

Yahoo | November 21, 2022

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the receipt of a formal notification from the Staff at The Nasdaq Stock Market, LLC (“Nasdaq”) on November 10, 2022 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1). The Company was previously notified by the Staff at Na

Yahoo | November 16, 2022

H.C. Wainwright Sticks to Their Buy Rating for Aravive (ARAV)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aravive (ARAV - Research Report) today and set a price target of $7.00. The company's shares opened today at $1.40.According to TipRanks, Pantginis is an analyst with an average return of -19.7% and a 26.95% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Decibel Therapeutics, and Biomea Fusion.Aravive has an analyst consensus of Strong Buy, with a price target consensus of $9.67, which is a 590.71% upside from current levels. In a report released on October 27, Roth Capital also maintained a Buy rating on the stock with a $10.00 price target.

Jason Carr on TipRanks | November 10, 2022

Aravive (ARAV) Reports Q3 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of 20.31% and 298.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

Continued Advancement of Clinical Trials in Platinum Resistant Ovarian Cancer (PROC), Clear Cell Renal Cell Carcinoma and Pancreatic AdenocarcinomaSecured Funding to Take the Company Beyond the PROC Readout in Mid-2023Advanced Development of Batiraxcept in China and Received Significant Milestone Payment HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today

Yahoo | November 10, 2022

Analysts Estimate Roivant Sciences Ltd. (ROIV) to Report a Decline in Earnings: What to Look Out for

Roivant Sciences Ltd. (ROIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | November 7, 2022

Aravive Announces Approximately $41.5 Million Private Placement Financing

Priced At-The-Market with Substantial Participation from both New Life Sciences Specialist Investors as well as Large Existing InvestorsHOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) (“Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has entered into definitive agreements with new biotechnology investors, existing investors, Company management and Company Directors for the issuance and sale

Yahoo | October 25, 2022

Here's Why We're A Bit Worried About Aravive's (NASDAQ:ARAV) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | October 24, 2022

Analysts Offer Insights on Healthcare Companies: Aravive (ARAV), Keros Therapeutics (KROS) and Legend Biotech (LEGN)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aravive (ARAV – Research Report), Keros Therapeutics (KROS – Research Report) and Legend Biotech (LEGN – Research Report) with bullish sentiments. Aravive (ARAV) In a report released yesterday, Robert Hazlett from BTIG maintained a Buy rating on Aravive, with a price target of $26.00. The company's shares closed last Wednesday at $0.80, close to its 52-week low of $0.58. According to TipRanks.

Brian Anderson on TipRanks | October 12, 2022

Analysts’ Top Healthcare Picks: Aravive (ARAV), scPharmaceuticals (SCPH)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aravive (ARAV – Research Report), scPharmaceuticals (SCPH – Research Report) and Applied DNA Sciences (APDN – Research Report) with bullish sentiments. Aravive (ARAV) H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aravive today and set a price target of $26.00. The company's shares closed last Monday at $0.79, close to its 52-week low of $0.58. According to TipRanks.

Catie Powers on TipRanks | October 11, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5507 seconds.